CN100411660C - Chinese medicine composition for treating optic atrophy and preparing method therefor - Google Patents
Chinese medicine composition for treating optic atrophy and preparing method therefor Download PDFInfo
- Publication number
- CN100411660C CN100411660C CNB2006100569910A CN200610056991A CN100411660C CN 100411660 C CN100411660 C CN 100411660C CN B2006100569910 A CNB2006100569910 A CN B2006100569910A CN 200610056991 A CN200610056991 A CN 200610056991A CN 100411660 C CN100411660 C CN 100411660C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- present
- folium ginkgo
- ginkgo extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a traditional Chinese medicine composition used for treating optic atrophy. The present invention is mainly prepared from wolfberry fruit, glossy privet fruit, herba ecliptae, extract of ginkgo leaf and grassleaf sweetflag rhizome, which are proportioned according to certain weight. The present invention can be prepared into any kinds of preparations for oral administration. The traditional medicine of the present invention performs the functions of nourishing the liver and the kidney, promoting blood circulation to remove meridian obstruction, inducing resuscitation and improving eyesight, and the present invention has better therapeutic effect on optic atrophy.
Description
[technical field]
The present invention relates to a kind of Chinese medicine composition that is used for the treatment of optic atrophy and preparation method thereof, belong to the field of Chinese medicines.
[background technology]
Optic atrophy belongs to motherland's medical science optic atrohic blindness category, is the common chronic fundus oculi disease of ophthalmology, and the patient vision occurs and fades, and the visual function serious hindrance finally causes losing one's sight, and is the ophthalmology serious symptom.Its pathogenic factor complexity, the various diseases of optic nerve comprises inflammation, ischemia, wound, compressing etc., all can cause retina axonal degeneration atrophy.At present this disease still there is not special effective Therapeutic Method, a large amount of neurotrophy medicines of clinical main application and vasodilation, effect is not good enough.Chinese patent is openly crossed the Chinese medicine for the treatment of optic atrophy, as: being used for that CN1544072, CN1119944, CN1130518, the prescription of these patents are not successful as yet is clinical, and the recipe ingredient complexity, expensive raw material price.
[summary of the invention]
Therefore, people exist widespread demand to the Chinese medicine preparation of treatment optic atrophy.Up to now, also do not find the report of any relevant pharmaceutical composition of the present invention.The inventor through repeatedly research, and by zooperal repeatedly the checking, found the optic nerve protection oral medicinal herb medicine of determined curative effect finally, thereby finished the present invention.
This medicine is made up of Fructus Lycii, Fructus Ligustri Lucidi, Herba Ecliptae, Folium Ginkgo and Rhizoma Acori Graminei, and the monarch drug Fructus Lycii has the effect of nourishing the liver and kidney, replenishing vital essence to improve eyesight in the side.The ministerial drug Fructus Ligustri Lucidi has the effect of invigorating the liver and kidney, clearind deficient heat, bright eyes in the side.Ministerial drug Herba Ecliptae liver and kidney tonifying in the side, cooling blood for hemostasis, with the Fructus Ligustri Lucidi mutual reinforcement between be usefulness, strengthen the merit of monarch drug the liver and the kidney tonifying.The adjuvant drug Folium Ginkgo has the merit of blood circulation promoting and blood stasis dispelling in the side, assists the unobstructed blood network of monarch drug, makes the essence and blood sending nutrient upward to eye.The messenger drug Rhizoma Acori Graminei has the merit of the circulation of qi promoting of having one's ideas straightened out in the side, be harmonious with monarch, minister, adjuvant drug, and the collateral dredging of having one's ideas straightened out, the up order key of medicine carrying, collaborative and control the order disease.More than five medicines, collect invigorating the liver and kidney, invigorate blood circulation, have one's ideas straightened out in a side, complement each other, empty person must be mended, stasis of blood person must be logical, strongly fragrant person must separate, altogether tool nourishing the liver and kidney, promoting blood circulation to remove obstruction in the collateral, the merit of having one's ideas straightened out and making eye bright.
During prescription of the present invention was formed, the weight proportion of each component was as follows:
Fructus Lycii 2-6 part, Fructus Ligustri Lucidi 1-5 part, Herba Ecliptae 1-5 part, Folium Ginkgo extract 0.05-0.25 part and Rhizoma Acori Graminei 0.5-2.5 part
The proportioning of preferred each component was as follows during prescription of the present invention was formed:
Fructus Lycii 3-5 part, Fructus Ligustri Lucidi 2-4 part, Herba Ecliptae 2-4 part, Folium Ginkgo extract 0.1-0.2 part and Rhizoma Acori Graminei 1-2 part
Most preferred proportioning is as follows:
1.5 parts of 4 parts of Fructus Lycii, 3 parts of Fructus Ligustri Lucidi, 3 parts of Herba Ecliptaes, 0.15 part of Folium Ginkgo extract and Rhizoma Acori Graminei
Folium Ginkgo extract described in the present invention is the extract of being processed into by Folium Ginkgo.
Chinese medicine composition of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.For example these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Can be with these crude drug decocting together except that the Folium Ginkgo extract, the condensed water decocting liquid is mixed and made into Folium Ginkgo extract more then.Bring into play drug effect better for each raw material that makes this medicine, preferentially Rhizoma Acori Graminei has been carried out vapor distillation and extracted its volatile oil.But these can not be used to limit protection scope of the present invention.
Preferably, the preparation method of Chinese medicine active component of the present invention is as follows:
A. the Rhizoma Acori Graminei of described weight proportion is soaked, it is standby to extract volatile oil with steam distillation, and the aqueous solution after distillation device is in addition collected, and is solution 1;
B. Fructus Lycii, Fructus Ligustri Lucidi, the Herba Ecliptae three flavor medicines with a Chinese medicine slag and described weight proportion decoct with water three times, and collecting decoction is solution 2;
C. merge solution 1 and solution 2, filter, being concentrated into relative density is the medicinal liquid of 1.08-1.10 (55 ℃), spray drying, get fine powder, add the Folium Ginkgo extract and an amount of dextrin of described weight proportion again, evenly mixed, spray into volatile oil, just be prepared into the active component of Chinese medicine composition of the present invention.
Preferably, above-mentioned c step increases precipitate with ethanol, and the preparation method of Chinese medicine active component of the present invention is:
C. merge solution 1 and solution 2, filter, being concentrated into relative density is the medicinal liquid of 1.08-1.10 (55 ℃), adds 90-95% ethanol and carries out precipitate with ethanol, reclaims ethanol and concentrated, spray drying, get fine powder, add the Folium Ginkgo extract and an amount of dextrin of described weight proportion again, evenly mixed, spray into volatile oil, just be prepared into the active component of Chinese medicine composition of the present invention.
The active component of Chinese medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, be prepared into any peroral dosage form commonly used as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine, as pill, powder, tablet, capsule, granule, oral liquid etc.
The effect that Chinese medicine composition of the present invention has nourishing the liver and kidney, promoting blood circulation to remove obstruction in the collateral, has one's ideas straightened out and make eye bright is used for the treatment of optic atrophy.
Chinese medicine composition of the present invention shows good curative effect through zoopery, below is experiment content:
Chinese medicine composition of the present invention crushes the research of model ganglion cell protective effect to the rat optic nerve
Test method
50 SD male rats are divided into 5 groups at random, i.e. negative control group, positive controls and high, normal, basic medication group, 10 every group.Each organizes the rat right eye is harmed eye, and left eye is not done the optic nerve clamping, as normal control.Rats by intraperitoneal injection 2% pentobarbital sodium 3ml/kg anaesthetizes, and cuts off outer canthus, cuts off bulbar conjunctiva and do corresponding separation under operating microscope, exposes optic nerve.Be clipped in behind the ball 2mm place clamping optic nerve 60 seconds with the miniature optic nerve of chucking power 40g, recover bulbar conjunctiva and also sew up the outer canthus wound.Visible one property crossed optical fundus blood vessel spasm crushes in back 2 minutes and recovers fully during the clamping optic nerve.Negative control group, positive controls, low dosage medication group, middle dosage medication group and high dose medication group crushed back 2 hours and after this used respectively every day the Chinese medicine composition gastric infusion of the present invention of normal saline, 4.69% YIMAIKANH, 65.6g crude drug/100ml, 32.8g crude drug/100ml, 16.4g crude drug/100ml in optic nerve, 4ml/kg, the excessive anaesthetic of animal lumbar injection is put to death after continuous 28 days.
Animal preceding 5 days at mercy killing is adopted the retrograde labelling retinal ganglial cells of two superior colliculus injections.2% pentobarbital sodium 3ml/kg lumbar injection makes Animal Anesthesia, is fixed on the brain solid positioner, and dental burr is bored and opened skull, draw 3% fluorogold with microsyringe, every side superior colliculus inject 2 points (5.9mm and 6.4mm behind the bregma, 1.4mm is opened on the side, dark 4.0mm), every some injection 1.5ul.
Animal peace after death, bulbar conjunctiva is located with the suture labelling in 12 of tops, takes out eyeball immediately and is fixed in 10% formalin solution 2 hours.0.5mm cuts off eyeball behind the limbus of corneae, removes cornea and crystalline lens, separates retina and with its directed tiling, natural drying in the air.Commercially available colourless nial polish mounting.Fluorescence microscope is taken pictures (AH-2 Olympic Ba Si company Japan), and distance is looked nipple center 2mm and respectively taken pictures up and down one, photo amplification 125 *.Use the Mustek of association scanner that photo is swept computer with 100dpi, use grading analysis software (CPAS) to carry out ganglion cell's counting, 4 photo ganglion cell quantity add up up and down, and change into ganglion cell's density.Right eye ganglion cell density is defined as ganglion cell's survival rate with the ratio of left eye ganglion cell density, i.e. ganglion cell's survival rate=right eye ganglion cell density/left eye ganglion cell density * 100%.
The result
Experimental result shows that the average survival rate of negative control group ganglion cell is 40.88%, and positive controls, low dosage medication group, middle dosage medication group and high dose medication group ganglion cell's survival rate is respectively 59.34%, 52.66%, 59.39% and 63%.Each is organized ganglion cell's survival rate and meansigma methods and standard deviation thereof and sees Table 1.
Table 1. is respectively organized ganglion cell's survival rate, meansigma methods and standard deviation
Each one factor analysis of variance of organizing ganglion cell's survival rate shows, has significant difference (p＜0.05) between them.Relatively show in twos, have significant difference (p＜0.05) between the negative control group low dosage medication group, and have highly significant difference (p＜0.01) between positive controls, middle dosage medication group and the high dose medication group.The Chinese medicine composition of the present invention that positive control medicine YIMAIKANH and three dosage groups are described can both be protected retinal ganglial cells effectively, each the group between relatively see Table 2 in twos.
Table 2. is respectively organized the comparing in twos of ganglion cell's survival rate (p value)
Among the medication group, there is significant difference (p=0.014) between low dosage medication group and the negative control group, there is significant difference (p=0.03) between high dose medication group and the low dosage medication group, and unknown significance difference (p=0.438) between high dose medication group and the middle dosage medication group, but its ganglion cell's survival rate still increases, and brings up to 63% from 59.39%.
Conclusion
By above evidence, Chinese medicine composition of the present invention has significant protective effect to rat retinal ganglion cell.
The specific embodiment:
Further illustrate the preparation method of Chinese medicine composition of the present invention by the following examples.
The capsule preparation of [embodiment 1] Chinese medicine composition of the present invention
A) Rhizoma Acori Graminei 1.5g is added 8 times of amounts of water, soaked 4 hours, extracted volatile oil 8 hours with steam distillation, volatile oil is standby, and the aqueous solution after distillation device is in addition collected, and is solution 1;
B) 3 flavor medicines with a) Chinese medicine slag and Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3g add 10 times of amounts of water, decoct three times, and each 1 hour, collecting decoction was solution 2;
C) merge solution 1 and solution 2, filter, being concentrated into relative density is the medicinal liquid of 1.08-1.10 (55 ℃), spray drying, get fine powder, add Folium Ginkgo extract 0.15g, add suitable amount of sucrose and starch again, or add an amount of dextrin, evenly mixed, dry method is made granule, sprays into volatile oil, airtight 2 hours, incapsulate.
The granule preparation of [embodiment 2] Chinese medicine composition of the present invention
A) Rhizoma Acori Graminei 1.5g is added 8 times of amounts of water, soaked 4 hours, extracted volatile oil 8 hours with steam distillation, volatile oil is standby, and the aqueous solution after distillation device is in addition collected, and is solution 1;
B) 3 flavor medicines with a) Chinese medicine slag and Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3g add 10 times of amounts of water, decoct three times, and each 1 hour, collecting decoction was solution 2;
C) merge solution 1 and solution 2, filter, being concentrated into relative density is the medicinal liquid of 1.08-1.10 (55 ℃), and spray drying gets fine powder, add Folium Ginkgo extract 0.15g, add suitable amount of sucrose and starch again, or add an amount of dextrin, make granule, drying adds volatile oil, mixing, promptly.
The preparation tablets of [embodiment 3] Chinese medicine composition of the present invention
A) Rhizoma Acori Graminei 1.5g is added 8 times of amounts of water, soaked 4 hours, extracted volatile oil 8 hours with steam distillation, volatile oil is standby, and the aqueous solution after distillation device is in addition collected, and is solution 1;
B) 3 flavor medicines with a) Chinese medicine slag and Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3g add 10 times of amounts of water, decoct three times, and each 1 hour, collecting decoction was solution 2;
C) merge solution 1 and solution 2, filter, being concentrated into relative density is the medicinal liquid of 1.08-1.10 (55 ℃), and spray drying gets fine powder, add Folium Ginkgo extract 0.15g, add cane sugar powder and starch again, evenly mixed, make granule, drying, add volatile oil, mixing, compacting is in blocks, promptly.
The oral liquid preparation of [embodiment 4] Chinese medicine composition of the present invention
A) Rhizoma Acori Graminei 1.5g is added 8 times of amounts of water, soaked 4 hours, extracted volatile oil 8 hours with steam distillation, volatile oil is standby, and the aqueous solution after distillation device is in addition collected, and is solution 1;
B) 3 flavor medicines with a) Chinese medicine slag and Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3g add 10 times of amounts of water, decoct three times, and each 1 hour, collecting decoction was solution 2;
C) merge solution 1 and solution 2, filter, be concentrated in right amount, add an amount of 95% ethanol and make precipitation, get supernatant and filter, filtrate concentrates.Add Folium Ginkgo extract 0.15g, add an amount of sucrose again, or add proper honey, sodium benzoate, and add suitable quantity of water, filter, embedding, sterilization, promptly.
The powder preparation of [embodiment 5] Chinese medicine composition of the present invention
Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3, Rhizoma Acori Graminei 1.5g are ground into fine powder, sieve, add Folium Ginkgo extract 0.15g, mixing, promptly.
The pill preparation of [embodiment 6] Chinese medicine composition of the present invention
Fructus Lycii 4g, Fructus Ligustri Lucidi 3g, Herba Ecliptae 3, Rhizoma Acori Graminei 1.5g are ground into fine powder, sieve, add Folium Ginkgo extract 0.15g, mixing adds an amount of refined honey and an amount of water pill again, and drying is made water-honeyed pill; Or add an amount of refined honey and make small honey pill or big honeyed pills, promptly.
Claims (8)
1. a Chinese medicine composition for the treatment of optic atrophy is characterized in that the crude drug for preparing this Chinese medicine composition consists of: Fructus Lycii 2-6 part, Fructus Ligustri Lucidi 1-5 part, Herba Ecliptae 1-5 part, Folium Ginkgo extract 0.05-0.25 part, Rhizoma Acori Graminei 05-2.5 part.
2. the Chinese medicine composition of claim 1, described proportioning is Fructus Lycii 3-5 part, Fructus Ligustri Lucidi 2-4 part, Herba Ecliptae 2-4 part, Folium Ginkgo extract 0.1-0.2 part, Rhizoma Acori Graminei 1-2 part.
3. the Chinese medicine composition of claim 1, described proportioning are 15 parts of 4 parts of Fructus Lycii, 3 parts of Fructus Ligustri Lucidi, 3 parts of Herba Ecliptaes, 0.15 part of Folium Ginkgo extract and Rhizoma Acori Graminei.
4. the arbitrary Chinese medicine composition of claim 1-3 is characterized in that described compositions is pill, powder, tablet, capsule or oral liquid.
5. the arbitrary Chinese medicine composition of claim 1-3 is characterized in that described compositions is a capsule.
6. the preparation method of the Chinese medicine composition of claim 5 is characterized in that, prepares according to the following step:
A. Rhizoma Acori Graminei is soaked, it is standby to extract volatile oil with steam distillation, and the aqueous solution after distillation device is in addition collected;
B. a Chinese medicine slag and Fructus Lycii, Fructus Ligustri Lucidi, Herba Ecliptae three flavor medicines are decocted with water collecting decoction three times;
C. the decocting liquid of the aqueous solution of combining step a and step b filters, and concentrates, and obtains the medicinal liquid that relative density is 1.08-1.10 under 55 ℃, and spray drying gets fine powder, adds Folium Ginkgo extract and an amount of dextrin again, and is evenly mixed, sprays into the volatile oil of step a.
7. the preparation method of the Chinese medicine composition of claim 5, the another kind of method of step c is: the decocting liquid of the aqueous solution of combining step a and step b, filter, and concentrate, under 55 ℃, obtain the medicinal liquid that relative density is 1.08-1.10, add 90-95% ethanol and carry out precipitate with ethanol, reclaim ethanol and concentrate spray drying, get fine powder, add the Folium Ginkgo extract and an amount of dextrin of described weight proportion again, mix evenly, spray into the volatile oil of step a.
8. the Chinese medicine composition of claim 1-5 is in a kind of purposes for the treatment of in the optic atrophy medicine of preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100569910A CN100411660C (en) | 2006-03-09 | 2006-03-09 | Chinese medicine composition for treating optic atrophy and preparing method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100569910A CN100411660C (en) | 2006-03-09 | 2006-03-09 | Chinese medicine composition for treating optic atrophy and preparing method therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850218A CN1850218A (en) | 2006-10-25 |
| CN100411660C true CN100411660C (en) | 2008-08-20 |
Family
ID=37131730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100569910A Expired - Fee Related CN100411660C (en) | 2006-03-09 | 2006-03-09 | Chinese medicine composition for treating optic atrophy and preparing method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100411660C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768479A (en) * | 2013-11-15 | 2014-05-07 | 广州市云桥生物科技有限公司 | Traditional Chinese medicine effective part composition for treating optic nerve atrophy |
| CN105311424B (en) * | 2014-11-14 | 2019-09-10 | 北京市眼科研究所 | A kind of Chinese medicine composition and preparation method thereof for treating visual fatigue |
| CN105125865A (en) * | 2015-08-25 | 2015-12-09 | 何萍萍 | Traditional Chinese medicine for treating optic atrophy |
| CN105853593B (en) * | 2016-05-17 | 2020-11-24 | 湖南中医药大学 | Pharmaceutical composition with optic nerve protection effect and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119944A (en) * | 1994-05-10 | 1996-04-10 | 林盛红 | Traditional Chinese medicine preparation for treating cataract, glaucoma and optic nerve wither |
-
2006
- 2006-03-09 CN CNB2006100569910A patent/CN100411660C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1119944A (en) * | 1994-05-10 | 1996-04-10 | 林盛红 | Traditional Chinese medicine preparation for treating cataract, glaucoma and optic nerve wither |
Non-Patent Citations (4)
| Title |
|---|
| 中医治疗视神经萎缩的研究近况. 肖红玲，张彬，曾亚平，孙立虹，张旭升.河北中医药学报，第20卷第4期. 2005 |
| 中医治疗视神经萎缩的研究近况. 肖红玲，张彬，曾亚平，孙立虹，张旭升.河北中医药学报，第20卷第4期. 2005 * |
| 中华人民共和国药典. 国家药典委员会，281-282，化学工业出版社. 2005 |
| 中华人民共和国药典. 国家药典委员会，281-282，化学工业出版社. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1850218A (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN102631558B (en) | Medicament for treating eye disease and preparation method of medicament | |
| CN100411660C (en) | Chinese medicine composition for treating optic atrophy and preparing method therefor | |
| CN101953936B (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN105963411A (en) | Traditional Chinese medicine composition for alleviating asthenopia, preparation of traditional Chinese medicine composition and preparation method thereof | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| JP2002154979A (en) | Medicine composition for i type allergy and method for producing the same | |
| CN103223104A (en) | Traditional Chinese medicine composition for treating diabetes and preparation method | |
| CN109602817B (en) | Traditional Chinese medicine composition for treating osteoporosis caused by estrogen deficiency | |
| CN103040974B (en) | Traditional Chinese medicine compound eye drops for preventing cataract and preparation method thereof | |
| CN101632813B (en) | Novel traditional Chinese medicine composition for treating diabetes class eyeground haemorrhage and preparation method thereof | |
| CN102920911B (en) | Traditional Chinese medicine for treating keratoconjunctivitis sicca and preparation method thereof | |
| CN107029124B (en) | Traditional Chinese medicine composition for treating primary hypertension and preparation method thereof | |
| CN1311842C (en) | Medicine for treating chronic conjunctivitis | |
| CN100389782C (en) | Eyesight-improving capsule and preparation process thereof | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN109288984A (en) | A kind of Chinese medicine composition and its preparation method and application containing caulis lonicerae | |
| CN105616774A (en) | Traditional Chinese medicinal composition for treating optic atrophy and preparation method of traditional Chinese medicinal composition | |
| CN113995782B (en) | Application of composition containing selfheal to preparation of medicine for treating thyroid nodules | |
| CN108175818B (en) | Traditional Chinese medicine composition for treating glaucoma and preparation method and application thereof | |
| CN102973748A (en) | Chinese patent medicine granules for treating eyeground macular edema | |
| CN1052640C (en) | Pills replenishing bone marrow | |
| CN115154580B (en) | Traditional Chinese medicine composition for treating corneal pannus, medicine and preparation method of medicine | |
| CN1168277A (en) | Eyesight granule and its compounding process | |
| CN108653526B (en) | Traditional Chinese medicine formula for treating myasthenia gravis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080820 |